CN111948392B - 一种肝细胞癌pdx模型构建方法 - Google Patents
一种肝细胞癌pdx模型构建方法 Download PDFInfo
- Publication number
- CN111948392B CN111948392B CN202010635046.6A CN202010635046A CN111948392B CN 111948392 B CN111948392 B CN 111948392B CN 202010635046 A CN202010635046 A CN 202010635046A CN 111948392 B CN111948392 B CN 111948392B
- Authority
- CN
- China
- Prior art keywords
- gpc3
- pdx model
- tumor
- hepatocellular carcinoma
- model
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010073071 hepatocellular carcinoma Diseases 0.000 title claims abstract description 48
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title claims abstract description 39
- 238000010276 construction Methods 0.000 title claims abstract description 16
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 71
- 102100032530 Glypican-3 Human genes 0.000 claims abstract description 58
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims abstract description 58
- 230000005740 tumor formation Effects 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
- 210000001519 tissue Anatomy 0.000 claims description 34
- 230000014509 gene expression Effects 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 7
- 210000003855 cell nucleus Anatomy 0.000 claims description 4
- 238000000034 method Methods 0.000 abstract description 9
- 208000005623 Carcinogenesis Diseases 0.000 abstract description 4
- 230000036952 cancer formation Effects 0.000 abstract description 4
- 231100000504 carcinogenesis Toxicity 0.000 abstract description 4
- 230000002055 immunohistochemical effect Effects 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 231100000588 tumorigenic Toxicity 0.000 abstract description 2
- 230000000381 tumorigenic effect Effects 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 206010061598 Immunodeficiency Diseases 0.000 description 8
- 208000029462 Immunodeficiency disease Diseases 0.000 description 8
- 230000007813 immunodeficiency Effects 0.000 description 8
- 201000007270 liver cancer Diseases 0.000 description 7
- 208000014018 liver neoplasm Diseases 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 description 2
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000009790 vascular invasion Effects 0.000 description 2
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 241000027355 Ferocactus setispinus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 1
- -1 Ki67 Proteins 0.000 description 1
- 102100040120 Prominin-1 Human genes 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
参数 | 风险率 | 95%置信区间 | P |
GPC3 | 6.59 | 1.71-25.42 | 0.006 |
Ki-67 | 16.76 | 4.12-68.07 | <0.001 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010635046.6A CN111948392B (zh) | 2020-07-03 | 2020-07-03 | 一种肝细胞癌pdx模型构建方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010635046.6A CN111948392B (zh) | 2020-07-03 | 2020-07-03 | 一种肝细胞癌pdx模型构建方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111948392A CN111948392A (zh) | 2020-11-17 |
CN111948392B true CN111948392B (zh) | 2022-03-08 |
Family
ID=73339890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010635046.6A Active CN111948392B (zh) | 2020-07-03 | 2020-07-03 | 一种肝细胞癌pdx模型构建方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111948392B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115521898A (zh) * | 2021-11-04 | 2022-12-27 | 上海万何圆生物科技有限公司 | 肝癌类器官与nk细胞共培养的免疫细胞治疗方法及应用 |
CN115537395A (zh) * | 2021-11-04 | 2022-12-30 | 上海万何圆生物科技有限公司 | 一种肝癌类器官与TILs细胞共培养的治疗方法及其应用 |
CN114028586A (zh) * | 2021-11-25 | 2022-02-11 | 南昌大学附属口腔医院(江西省口腔医院) | 一种基于pdx模型研究阿帕替尼抗肿瘤作用效果的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106248945A (zh) * | 2016-08-02 | 2016-12-21 | 冯骥良 | 对肝细胞癌患者进行肝细胞癌根治切除术预后情况分组的方法、系统以及试剂盒 |
CN106619719A (zh) * | 2016-12-27 | 2017-05-10 | 中国科学院广州生物医药与健康研究院 | 一种检测嵌合抗原受体t细胞对肝癌细胞抑制作用的模型和方法 |
CN108474723A (zh) * | 2015-12-02 | 2018-08-31 | 克莱尔莱特诊断有限责任公司 | 制备和分析肿瘤组织样品用于检测和监测癌症的方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019524128A (ja) * | 2016-08-03 | 2019-09-05 | ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ | がんモデル化プラットフォームおよびその使用方法 |
-
2020
- 2020-07-03 CN CN202010635046.6A patent/CN111948392B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108474723A (zh) * | 2015-12-02 | 2018-08-31 | 克莱尔莱特诊断有限责任公司 | 制备和分析肿瘤组织样品用于检测和监测癌症的方法 |
CN106248945A (zh) * | 2016-08-02 | 2016-12-21 | 冯骥良 | 对肝细胞癌患者进行肝细胞癌根治切除术预后情况分组的方法、系统以及试剂盒 |
CN106619719A (zh) * | 2016-12-27 | 2017-05-10 | 中国科学院广州生物医药与健康研究院 | 一种检测嵌合抗原受体t细胞对肝癌细胞抑制作用的模型和方法 |
Non-Patent Citations (2)
Title |
---|
Establishment of a Liver Transplant Patient-derived Tumor Xenograft (PDX) Model Using Cryopreserved Pancreatic Ductal Adenocarcinoma;Ryota Tanaka 等;《ANTICANCER RESEARCH》;20200531;第40卷(第5期);第2637-2644页 * |
Using patient-derived xenograft models of colorectal liver metastases to predict chemosensitivity;Kai M Brown 等;《Journal of Surgical Research》;20180315;第227卷;第158-167页 * |
Also Published As
Publication number | Publication date |
---|---|
CN111948392A (zh) | 2020-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111948392B (zh) | 一种肝细胞癌pdx模型构建方法 | |
Allan et al. | Circulating tumor cell analysis: technical and statistical considerations for application to the clinic | |
Mattar et al. | Establishing and maintaining an extensive library of patient-derived xenograft models | |
Fiorentino et al. | Predictive value of biological markers for hepatocellular carcinoma patients treated with orthotopic liver transplantation | |
US20190078153A1 (en) | Method of analyzing genetically abnormal cells | |
US9857375B2 (en) | Cancer marker and utilization thereof | |
Eliasova et al. | Circulating tumor cells in different stages of colorectal cancer | |
CN105684989A (zh) | 一种肝癌pdx标准化模型库 | |
CN113142135A (zh) | 一种消化道肿瘤pdx模型及标准化模型库的构建方法 | |
CN104919315A (zh) | 个体化抗癌药剂的筛选系统 | |
CN107208131A (zh) | 用于肺癌分型的方法 | |
CN113462782A (zh) | 鼻咽癌标志物及其应用 | |
CN111793687B (zh) | 抑制肺腺癌的靶标crtac1及其应用 | |
Li et al. | Prostate specific antigen as a biomarker for breast cancer: a meta-analysis study | |
JP5527573B2 (ja) | Mcf7由来細胞 | |
JP6173577B1 (ja) | 細胞増殖法を用いた循環腫瘍細胞の検出・分離取得方法 | |
CN106148511A (zh) | 一种肝癌患者接受切除术后复发风险的预测标志物及试剂盒 | |
CN108467855B (zh) | 新的肺特异性转移肝癌细胞及其制备 | |
WO2018082037A1 (zh) | 利用猪特异游离dna监测异种移植免疫排斥反应的方法和引物 | |
US20220223227A1 (en) | Machine learning techniques for identifying malignant b- and t-cell populations | |
CN116434963A (zh) | 超米兰标准的肝细胞癌肝移植受者西罗莫司的疗效预测模型 | |
CN106434904A (zh) | 一种实时监控肝癌复发或转移的CD133、EpCAM和CK19联合检测试剂盒 | |
Grabowski et al. | Spatial immunosampling of MRI-defined glioblastoma regions reveals immunologic fingerprint of non-contrast enhancing, infiltrative tumor margins | |
WO2023034292A1 (en) | Methods of predicting long-term outcome in kidney transplant patients using pre-transplantation kidney transcriptomes | |
Terada et al. | P2. 04-41 Clinical and Immunological Factors Associated with Mutation Burden in Non-Small Cell Lung Cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Xu Xiao Inventor after: Zhuo Jianyong Inventor after: Lu Di Inventor after: Wang Jianguo Inventor after: Lian Zhengxing Inventor after: Zhang Jiali Inventor after: Li Huihui Inventor after: Cen Beini Inventor before: Zhuo Jianyong Inventor before: Lu Di Inventor before: Wang Jianguo Inventor before: Lian Zhengxing Inventor before: Zhang Jiali Inventor before: Li Huihui Inventor before: Cen Beini Inventor before: Xu Xiao |